Author is contrarian bullish on Novo Nordisk citing low P/E and Ozempic/diabetes franchise, expects long-run 10-bagger.
NVO — LONG Novo Nordisk trades at a P/E of 15, which the author considers underpriced. The author points to Ozempic and the diabetes franchise as key fundamental drivers. The author expects NVO to become a 10-bagger in the long run and is adding to a 21-share position.
P/E ratio of 15!!!!!!!!!!
This Reddit post, published January 09, 2026, features u/Same-Kiwi-6360 discussing NVO. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Same-Kiwi-6360 · Tickers: NVO